Komori
Kaken Pharmaceutical (4521) · RiskMitigated

Credit, foreign exchange, market and liquidity risks, and customer concentration

First written in FY2017. 3 of 7 entries say "Mitigated", first in FY2019. Latest entry: FY2026.

7entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMitigatedFY2019MitigatedFY20222017: 120172018: 120182019: 120192020: 020202021: 120212022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Credit, Market Price Volatility, and Liquidity Risk Management for Financial AssetsA theme 62 companies write about · 59 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 11 of 38 companies on the "Worse" side.

6 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 62 companies compared. The sentences above are computed from all 62.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「As of the balance-sheet date for the fiscal year, 51.4% of trade receivables were due from specific major customers.」

    Trade receivables concentration with specific major customers was 51.4%, down from the previously disclosed 59%. Concentration risk remains, but the disclosed concentration level has decreased.
  2. FY2026-H1RestatedAnnual report

    「The equity ratio was 83.4% (80.2% at the end of the previous fiscal year).」

    The policy of prioritising a strong equity base and high liquidity remains in place. The equity ratio rose from 80.2% at the end of the previous year to 83.4%.
  3. FY2022MitigatedAnnual report

    「As of the balance-sheet date for the fiscal year, 59% of trade receivables were due from specific major customers.」

    Trade receivables concentration with specific major customers declined from 61% in the previous year to 59%. Concentration risk remains, but the disclosed concentration level has decreased.
  4. FY2021RestatedAnnual report

    「As of the consolidated fiscal year-end, 61% of trade receivables were from a specific major customer.」

    Trade receivables concentration with specific major customers was 61%, unchanged from 61% in the previous annual report. The methods for managing credit, foreign exchange, market and liquidity risks continue to be disclosed.
  5. FY2019MitigatedAnnual report

    「As of the consolidated fiscal year-end, 61% of trade receivables were from a specific major customer.」

    Trade receivables concentrated in a specific major customer declined from 66% in the previous year to 61%. Concentration risk remains, but the disclosed level of concentration decreased.
  6. FY2018WorsenedAnnual report

    「As of the consolidated fiscal year-end, 66% of trade receivables were from a specific major customer.」

    Trade receivables concentrated in a specific major customer increased from 63% in the previous disclosure to 66%, expanding customer concentration exposure.
  7. FY2017First statedAnnual report

    「As of the consolidated fiscal year-end, 63% of trade receivables were from a specific major customer.」

    The disclosure states that 63% of trade receivables are concentrated in a specific major customer and describes credit risk, foreign exchange risk, market price risk, liquidity risk and their management.
Moved together

"Continuation of R&D investment" moved the same way as this thread, in the same document, in 3 of its 7 moves.

333222★123456
  1. ★This thread
  2. 1Continuation of R&D investment3×
  3. 2Strengthening the New Drug Pipeline and Accelerating Research and Development3×
  4. 3Implementation of Shareholder Returns3×
  5. 4Pharmaceutical licensing in Japan and overseas2×
  6. 5Clinical development pipeline progress2×
  7. 6Recording of overseas revenue2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.